Key Insights

Highlights

Treatment Research

2 treatments under study, led by Active Placebo Midazolam Infusion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Early Phase 1 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07408193Early Phase 1RecruitingPrimary

The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain.

Showing all 1 trials

Research Network

Common Treatments

  • Active Placebo Midazolam Infusion1
  • Lidocaine And Ketamine Infusion1

Active Sponsors

  • Attikon Hospital1
  • National and Kapodistrian University of Athens1

Top Investigators

Activity Timeline